| http://www.w3.org/ns/prov#value | - Development of clear, precise indicators of disease severity (e.g. clinical signs and symptoms, virology measures, immune response measures, biomarkers, etc.) will improve the efficiency and decrease the cost of vaccine trials and will likely increase the number and variety of types of vaccine evaluated in clinical trials.???Define the protective and disease enhancing immune responses associated w
|
